Overview

In cardiovascular health, where high cholesterol poses a persistent threat to millions, this book explores advancements in gene editing and therapeutic interventions to achieve lasting control over lipid levels. Drawing on clinical studies and expert insights, it examines innovative treatments such as CRISPR-Cas9 gene therapy targeting the ANGPTL3 gene to permanently reduce LDL cholesterol and triglycerides, alongside emerging oral and injectable medications, such as elicitide and evolocumab, that enhance statin efficacy. The book extends to dietary approaches, including plant-based regimens that lower apoB and total cholesterol, while addressing challenges in patient adherence and the potential for synergistic strategies combining genetics, pharmacology, and lifestyle changes. Structured across three parts, the book examines the biological underpinnings of hyperlipidemia, evaluates current and experimental therapies, and outlines future directions for preventing heart disease through personalized, one-time solutions and ongoing management. Gain insight into: - A clear understanding of how genetic mutations and targeted gene editing can mimic natural protections against elevated cholesterol, empowering informed discussions with healthcare providers. - The mechanisms and trial outcomes of new drugs like PCSK9 inhibitors, enabling better evaluation of treatment options beyond traditional statins. - Practical knowledge on integrating plant-based diets with medical therapies to optimize lipid profiles and reduce cardiovascular risk over time. - Awareness of long-term safety considerations and compliance barriers, fostering realistic expectations for adopting innovative health strategies. - Guidance on emerging research phases and population-wide applications, preparing individuals to stay ahead in managing hereditary or lifestyle-driven cholesterol issues.

Full Product Details

9798274043915

Table of Contents

Reviews

Author Information

Tab Content 6

Countries Available